PRMT5 and neoplasm: Multiple PRMT5 inhibitors have been developed, such as GSK3326595 [55], JNJ-64619178 [56], and MRTX1719 [57], all of which significantly suppressed tumor growth in preclinical models and are being currently tested in clinical trials [58].